Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:15 PM
Ignite Modification Date:
2025-12-24 @ 10:15 PM
NCT ID:
NCT02815735
Eligibility Criteria:
Inclusion Criteria:
* Spherical distance CL (Contact Lens) prescription between -1.00 and -6.00D (Diopter) OR in both eyes (inclusive)
* Adapted soft CL wearers (i.e. \>1 month) who are reusable lens wearers\*
* Spectacle cylinder 0.75D in both eyes
* Correctable to 6/9 in both eyes
* Be between 18 and 34 years of age (inclusive)
* Able to read, comprehend and sign an informed consent
* Own a mobile phone and be able to respond to SMS survey during the period 8am - 8pm
* Willing to comply with the wear and study visit schedule
Exclusion Criteria:
Any of the following will render a subject ineligible for inclusion:
* Existing wearer of daily disposable contact lenses
* Known allergy to Opti-Free PureMoist multipurpose solution
* Any active corneal infection, injury or inflammation
* Systemic or ocular allergies, which might interfere with CL wear
* Systemic disease, which might interfere with CL wear
* Ocular disease, which might interfere with CL wear
* Strabismus or amblyopia
* Subjects who have undergone corneal refractive surgery
* Subjects with keratoconus or other severe corneal irregularity contraindicating lens wear
* Pregnant, planning a pregnancy or lactating
* Use of systemic/topical medication contraindicating CL wear
* Diabetic
* Site employees or family members of investigators
* Participation in any concurrent trial or in the last 30 days
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
34 Years
Study:
NCT02815735
Study Brief:
Protocol Section:
NCT02815735